Fiducient Advisors’s Quest Diagnostics DGX Stock Holding History

Fiducient Advisors’s Portfolio DGX Stock Details DGX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-2,825	Closed	-$442K	–	78
2022 Q4	$442K	Buy	+2,825	New	+$406K	0.13%	92

Other funds holding DGX

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fiducient Advisors's DGX Position: Q1 2023 in Review

Fiducient Advisors sold out of Quest Diagnostics (DGX) in Q1 2023, closing a stake of 2,825 shares — an estimated $442K sold.

Fiducient Advisors first reported a position in DGX in Q4 2022 and held it in 1 quarter. The position peaked at $442K in Q4 2022. 834 funds tracked by Wall St. Rank hold DGX as of Q1 2023.

Fiducient Advisors reported no remaining Quest Diagnostics position as of Q1 2023 after selling out during the quarter.
Fiducient Advisors sold 2,825 Quest Diagnostics shares in Q1 2023, an estimated $442K.
Fiducient Advisors first reported a position in Quest Diagnostics in Q4 2022 and held it in 1 quarter.
Fiducient Advisors's Quest Diagnostics position peaked at $442K in Q4 2022.
834 funds tracked by Wall St. Rank held Quest Diagnostics as of Q1 2023.

Based on Fiducient Advisors's 13F filing for Q1 2023, filed 8 May 2023.